Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

BACKGROUND: In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to identify antibody and cellular immune correlates of infection risk. METHODS: In pilot studies conducted with RV144 blood...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Haynes, Barton F., Gilbert, Peter B., McElrath, M. Juliana, Zolla-Pazner, Susan, Tomaras, Georgia D., Alam, S. Munir, Evans, David T., Montefiori, David C., Karnasuta, Chitraporn, Sutthent, Ruengpueng, Liao, Hua-Xin, DeVico, Anthony L., Lewis, George K., Williams, Constance, Pinter, Abraham, Fong, Youyi, Janes, Holly, DeCamp, Allan, Huang, Yunda, Rao, Mangala, Billings, Erik, Karasavvas, Nicos, Robb, Merlin L., Ngauy, Viseth, de Souza, Mark S., Paris, Robert, Ferrari, Guido, Bailer, Robert T., Soderberg, Kelly A., Andrews, Charla, Berman, Phillip W., Frahm, Nicole, De Rosa, Stephen C., Alpert, Michael D., Yates, Nicole L., Shen, Xiaoying, Koup, Richard A., Pitisuttithum, Punnee, Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Rerks-Ngarm, Supachai, Michael, Nelson L., Kim, Jerome H.
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3371689/
https://ncbi.nlm.nih.gov/pubmed/22475592
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1113425
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items